Amgen, AstraZeneca's severe asthma therapy Tezspire launches in Canada
matt_benoit         

Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) said on Wednesday that their asthma therapy TezspireÂ was now available in Canada.
TezspireÂ (tezepelumab injection), which was approved byÂ Health Canada in July 2022, is indicated as an add-on maintenance therapy for people 12 years and older with severe asthma.
The companies saidÂ Tezspire is the first and only biologic to consistently and significantly reduce exacerbations in a broad population of patients withÂ severe asthma.
The approval was based on data from a phase 2b trial calledÂ PATHWAYÂ and a phase 3 study, dubbed NAVIGATOR.
In September,Â Tezspire was approved in the EU and Japan for severe asthma.